Biodexa Pharmaceuticals Plc Aktie London S.E.
Aktien
A3D65A
GB00BNGF1L75
BDRX
Biotechnologie
Umsatz 2024 * | - | Umsatz 2025 * | - | Marktwert | 4.12 Mio. 5.17 Mio. 4.68 Mio. |
---|---|---|---|---|---|
Nettoergebnis 2024 * | - | Nettoergebnis 2025 * | - | EV / Sales 2024 * | - |
Nettoliquidität 2024 * | - 0 0 | Nettoliquidität 2025 * | - 0 0 | EV / Sales 2025 * | - |
KGV 2024 * |
-
| KGV 2025 * |
-
| Beschäftigte | 21 |
Rendite 2024 * |
-
| Rendite 2025 * |
-
| Streubesitz | 57.92% |
Manager | Titel | Alter | Seit |
---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09.09.19 |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 44 | 11.07.21 |
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 20.06.22 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 29.10.14 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09.09.19 |
% 1. Jan. | Kap. | |
---|---|---|
+8.96% | 105 Mrd. | |
-1.43% | 104 Mrd. | |
+4.40% | 22.94 Mrd. | |
-12.15% | 22.34 Mrd. | |
-4.36% | 19.25 Mrd. | |
-39.98% | 17.08 Mrd. | |
-10.04% | 16.96 Mrd. | |
+6.79% | 14.16 Mrd. | |
+38.61% | 12.63 Mrd. |